Abstracts Archive - Page 202 of 2425 - ACR Meeting Abstracts

Abstract Number: 0438 • ACR Convergence 2023
Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review
Swetha Ann Alexander¹, Gordon Starkebaum², Diana Louden², Grant Hughes² and Namrata Singh³, ¹University of Utah Health, Salt Lake City, UT, ²University of Washington, Seattle, WA, ³University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid Arthritis (RA) patients have an increased risk of developing lymphoma compared to the general population. This increased risk is believed to be linked…
Abstract Number: 0503 • ACR Convergence 2023
Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging
Siba Raychaudhuri¹, Yasser Abdelhafez², Dario Mazza², Smriti K Raychaudhuri³ and Abhijit Chaudhari⁴, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²University of California Davis, Sacramento, CA, ³VA Sacramento Medical Center, Mather, CA, ⁴UC Davis School of Medicine, Sacramento, CA
Background/Purpose: Right and Moll recognized the presence of spinal inflammation/axial disease in psoriatic arthritis (PsA) in their seminal work in 1973. The prevalence of axial…
Abstract Number: 0310 • ACR Convergence 2023
Implementing an Osteoarthritis Management Program to Deliver Guideline-Driven Care for Knee and Hip Osteoarthritis in a U.S. Academic Health System
Kathryn Miller¹, Divya Vundamati², Linda Baier¹, Roger Brown¹, Tommy Yue Yu¹ and Christie M. Bartels³, ¹University of Wisconsin, Madison, WI, ²UW Health, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: To assess patient outcomes from an Osteoarthritis Management Program (OAMP) situated in an academic medical center.Methods: Eligibility for this open cohort study included adults…
Abstract Number: 0311 • ACR Convergence 2023
Heterogeneity and Natural History of Medial Fixed Joint Space Width in Healthy Knees Among Women and Men: Data from Three Large Cohort Studies
Kent Kwoh¹, Erin Ashbeck², Edward Bedrick¹, Yvonne Golightly³, Zong-Ming Li¹, Jean liew⁴, Amanda Nelson⁵, Tuhina Neogi⁶, Xiaoxiao Sun¹ and Jeffrey Duryea⁷, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, Tucson, AZ, ³University of Nebraska Medical Center, Omaha, NE, ⁴Boston University, Boston, MA, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁶Boston University School of Medicine, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Radiographic joint space width (JSW) is commonly used to assess structural progression in randomized controlled trials and observational studies of knee osteoarthritis (KOA). No…
Abstract Number: 0528 • ACR Convergence 2023
Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis
Seong-Kyu kim¹, Ji-Won kim¹, Jun Sik Yoon², bo young Kim³, Hwajeong Lee¹, Sung-Hoon Park¹ and Jung-Yoon Choe¹, ¹Daegu Catholic University School of Medicine, Daegu, South Korea, ²Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea, ³Daegu Catholic University Medical Center, Daegu, South Korea
Background/Purpose: Ankylosing spondylitis (AS) is associated with increased cardiovascular disease, but there are limited data as to whether prolonged treatment with non-steroidal anti-inflammatory drugs (NSAIDs)…
Abstract Number: 0529 • ACR Convergence 2023
Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)
Michaela Koehm¹, Maximilian Klippstein², Sabine Kugler³, Sina Mackay³, Daniel Schulz³, Asmir Vodencarevic⁴, Guillaume Wendt⁴, Daniel Peterlik⁴, Uta Kiltz⁵, Jan Brandt-Juergens⁶ and Frank Behrens⁷, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Sankt Augustin, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with axial spondyloarthritis (axSpA). IL-17A inhibition has demonstrated good efficacy on axSpA.…
Abstract Number: 0332 • ACR Convergence 2023
Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis
Jeong Min Yu¹, John VanBuren², Angela Child², Jessica Alvey², Lisa Mandl³, Laura Pinheiro⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Ashima Makol¹⁶, Jerry Molitor¹⁷, Duncan Moore¹⁸, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah²¹, Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug²⁴, Virginia Steen²⁵, Elizabeth Volkmann²⁶ and Jessica Gordon¹, ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine College, New York, NY, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Columbia University, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁶Mayo Clinic, Rochester, MN, Rochester, MN, ¹⁷University of Minnesota, Minneapolis, MN, ¹⁸Northwestern Memorial Hospital, Chicago, IL, ¹⁹Northwestern University, Riverside, IL, ²⁰University of Pennsylvania, Philadelphia, PA, ²¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²²Duke University, Durham, NC, ²³Victoria Shanmugam, MD, Great Falls, VA, ²⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶University of California Los Angeles, Los Angeles, CA
Background/Purpose: Skin disease is a hallmark of systemic sclerosis (SSc). The modified Rodnan skin score (mRSS) is physician performed measurement that assesses the extent and…
Abstract Number: 0516 • ACR Convergence 2023
Drivers of Treatment Intensification in Patients with Axial Spondyloarthritis and High Disease Activity: Results from a Clinical Practice Registry
Casper Webers¹, Rabab Nezam El-Din¹, Marin Been¹, Harald Vonkeman² and Astrid van Tubergen¹, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, ²Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands
Background/Purpose: In the management of axial spondyloarthritis (axSpA), treatment intensification (TI) is recommended in patients with high disease activity (HDA). However, in practice, in most…
Abstract Number: 0519 • ACR Convergence 2023
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and Its Open-Label Extension
Atul Deodhar¹, Victoria Navarro-Compán², Denis Poddubnyy³, Lianne Gensler⁴, Sofia Ramiro⁵, Tetsuya Tomita⁶, Helena Marzo-Ortega⁷, Carmen Fleurinck⁸, Thomas Vaux⁹, Ute Massow¹⁰, Désirée van der Heijde⁵ and Xenofon Baraliakos¹¹, ¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Graduate School of Health Science, Morinomiya University of Medical Science, Osaka, Japan, ⁷NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim am Rhein, Germany, ¹¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody, selectively inhibits IL-17F in addition to IL17A. BKZ has demonstrated clinical efficacy and safety up to 3 years…
Abstract Number: 0558 • ACR Convergence 2023
Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment
Carolina Munoz-Grajales¹, Michelle Barraclough², Juan Pablo Diaz Martinez³, Jiandong Su², Kathleen Bingham², Mahta Kakvan⁴, Roberta Kretzmann⁵, Carmela Tartaglia⁶, Lesley Ruttan⁷, May Choi⁸, Simone Appenzeller⁹, Sherief Marzouk⁵, Dennisse Bonilla², Patti Katz¹⁰, Dorcas Beaton¹¹, Robin Green⁵, Joan Wither² and Zahi Touma⁵, ¹UHN/TWH, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹UNICAMP, Campinas, Brazil, ¹⁰University of California San Francisco, San Rafael, CA, ¹¹Institute for Work & Health, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Studies have reported that SLE patients with different…
Abstract Number: 0342 • ACR Convergence 2023
Assessing the Known-group Validity of the IDEOM MSK-Q Using Data from the National Psoriasis Foundation Annual Survey
Lourdes Perez-Chada¹, George Gondo², Joseph F. Merola³ and Alice B. Gottlieb⁴, ¹Brigham and Women's Hospital, Boston, MA, ²National Psoriasis Foundation, Alexandria, VA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: The IDEOM MSK-Q aims to assess MSK symptoms in individuals with psoriatic disease. It consists of 3 subscales: Intensity of MSK Symptom (3 items),…
Abstract Number: 0534 • ACR Convergence 2023
Tapering Tofacitinib for Axial Spondyloarthritis in Remission or Low-disease Activity State
Pankti Mehta¹, Sanjo Saijan², Justin George², Sakir Ahmed³, Bhowmik Meghnathi⁴ and Padmanabha Shenoy², ¹King George's Medical University, Mumbai, India, ²Centre for arthritis and rheumatism excellence, Kochi, India, ³Kalinga Institute of Medical Sciences, Bhubaneswar, India, ⁴Smt. NHL Municipal Medical College and SVP hospital, CIMS Hospital, Ahmedabad, India
Background/Purpose: The recent recommendations from EULAR-ASAS for Axial Spondyloarthritis (AxSpA) call for decreasing biologic (b)DMARDs after an extended period of remission. This is especially relevant…
Abstract Number: 0458 • ACR Convergence 2023
Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience
Maria Rodriguez Laguna¹, Zulema Rosales-Rosado², Cristina Vadillo-Font¹, Jose Pierre Otazu-Moudelle¹, Inés Pérez Sancristóbal¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone an enormous change in the last two decades with the use of biological Disease Modifying Drugs…
Abstract Number: 0476 • ACR Convergence 2023
Factors Associated with the Need for Assisted Reproductive Therapies in a Spanish Cohort of Patients with Rheumatic Diseases
Antía García-Fernández¹, Fernando Rengifo-García¹, Raquel Senosiain-Echarte¹, Miguel álvaro-Navidad¹, Miguel A Gonzalez-Gay² and Juan A Martínez-López¹, ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Patients with rheumatic diseases (RMD) have a lower pregnancy rate, with infertility being one of the main causes. The rate of assisted reproductive therapies…
Abstract Number: 0364 • ACR Convergence 2023
Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis
Adam Mayer¹, Timothy G. Brandon², Pamela F. Weiss³ and on behalf of the JAXSPERT members², ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The extent to which heterogeneity exists in youth with axial disease and juvenile spondyloarthritis (JSpA) is unclear. In a cross-sectional sample of patients classified…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].